Tralokinumab-ldrm (Adbry™) was approved in December 2021 for the treatment of moderate-to severe atopic dermatitis (AD) in adults 18 years or older. The mechanism of tralokinumab is that it binds to and inhibits IL-13, which is a key driver of AD signs and symptoms.
Biologic for Atopic Dermatitis FDA Approved
